Direct anterior approach vs Hardinge in obese and nonobese osteoarthritic patients: A randomized controlled trial

George Macheras; Sophia Stasi; Michail Sarantis; Athanasios Triantafyllou; Dimitrios Tzefronis; Stamatios A Papadakis

doi:10.5312/wjo.v12.i11.877

Direct anterior approach vs Hardinge in obese and nonobese osteoarthritic patients: A randomized controlled trial

World J Orthop. 2021 Nov 18;12(11):877-890. doi: 10.5312/wjo.v12.i11.877.

Authors

George Macheras¹, Sophia Stasi², Michail Sarantis¹, Athanasios Triantafyllou³, Dimitrios Tzefronis¹, Stamatios A Papadakis⁴

Affiliations

¹ 4Orthopaedic Department, "KAT" General Hospital of Attica, Athens 14561, Kifissia, Greece.
² Laboratory of Neuromuscular and Cardiovascular Study of Motion (LANECASM), Physiotherapy Department, University of West Attica, Athens 12243, Egaleo, Greece. stasi@uniwa.gr.
³ Laboratory of Neuromuscular and Cardiovascular Study of Motion (LANECASM), Physiotherapy Department, University of West Attica, Athens 12243, Egaleo, Greece.
⁴ 2Orthopaedic Department, "KAT" General Hospital of Attica, Athens 14561, Kifissia, Greece.

Abstract

Background: The increased prevalence of obesity has resulted in orthopedic surgeons being likely to face many patients with a high body mass index (BMI) who warrant total hip arthroplasties (THAs) over the coming years. Studies' findings considered the postoperative clinical, and functional outcomes in these patients are controversial, and selecting the most appropriate surgical approach remains debatable.

Aim: To compare pain-levels, functionality, and quality-of-life in obese and nonobese osteoarthritic patients who have undergone primary total hip arthroplasty through either direct-anterior-approach (DAA) or Hardinge-approach.

Methods: One hundred and twenty participants (> 50 years) were divided into four groups according to the surgical approach (DAA or Hardinge) and patients' BMI (nonobese < 30 kg/m² vs obese ≥ 30 kg/m²). Outcomes were measured preoperatively and postoperatively (6^th and 12^th week). Pain was measured with Face Pain Scale-Revised (FPS-R). Functionality was measured with Timed Up & Go (TUG) test and Modified Harris Hip Score-Greek version (MHHS-Gr). Quality-of-life was evaluated with the 12-item-International Hip Outcome Tool-Greek version (iHOT12-Gr) (Clinical Trial Identifier: ISRCTN15066737).

Results: DAA vs Hardinge: (week 6) DAA-patients showed 12.2% less pain, more functionality (14.8% shorter TUG-performance time, 21.5% higher MHHS-Gr), and 38.16% better quality-of-life (iHOT12-Gr) compared to Hardinge-patients (all P values < 0.001). These differences were further increased on week 12 (all P values ≤ 0.05)]. DAA-obese vs Hardinge-obese: (week 6) DAA-obese patients had less pain, shorter TUG-performance time, better MHHS-Gr and iHOT12-Gr scores than Hardinge-obese (all P values < 0.01). (Week 12) Only the TUG-performance time of DAA-obese was significantly shortened (22.57%, P < 0.001). DAA-nonobese vs DAA-obese: no statistically significant differences were observed comparing the 6^th and 12^th weeks' outcomes.

Conclusion: DAA-groups reported less pain, more functionality and better quality-of-life, compared to the Hardinge-groups. The DAA benefited obese and nonobese patients, similarly yet faster, suggesting that it should be the more preferred choice for obese patients, instead of Hardinge. However, more comparative studies with more extended follow-up periods are needed to confirm our results and better evaluate all patients' long-term outcomes.

Keywords: Functional ability; Obesity; Osteoarthritis; Pain; Quality-of-life; Total hip arthroplasty.

Publication types

Clinical Trial